MCID: GLC003
MIFTS: 56

Glucose Intolerance

Categories: Metabolic diseases

Aliases & Classifications for Glucose Intolerance

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 29 55 6 44 15
Impaired Glucose Tolerance 73
Malabsorption of Glucose 12
Fatty Stool 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10603
ICD10 33 R73.09
MeSH 44 D018149
NCIt 50 C34646
UMLS 73 C0271650

Summaries for Glucose Intolerance

MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and apnea, obstructive sleep. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA Leucine 1 (UUA/G)), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Metformin and Saxagliptin have been mentioned in the context of this disorder. Affiliated tissues include ovary, heart and kidney, and related phenotypes are adipose tissue and homeostasis/metabolism

Related Diseases for Glucose Intolerance

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 32.3 INS LEP LMNA
2 apnea, obstructive sleep 30.5 ADIPOQ INS LEP
3 coronary heart disease 1 30.4 ADIPOQ INS LPL RETN
4 hyperproinsulinemia 30.4 IGFBP1 INS SHBG
5 arteries, anomalies of 30.3 ADIPOQ INS LEP
6 hyperinsulinemic hypoglycemia 30.0 GCK INS INSR
7 acromegaly 29.9 GHRL IGF1 IGFBP1 INS
8 hyperthyroidism 29.8 GHRL INS LEP SHBG
9 coronary artery anomaly 29.7 ADIPOQ INS IRS1 LPL RETN
10 turner syndrome 29.6 IGF1 IGFBP1 SHBG
11 hyperandrogenism 29.5 IGF1 IGFBP1 INS INSR SHBG
12 chronic kidney failure 29.4 ADIPOQ IGF1 INS LEP
13 polycystic ovary syndrome 29.3 IGF1 IGFBP1 INS INSR IRS1 LEP
14 anovulation 29.0 IGF1 IGFBP1 INS LEP SHBG
15 fatty liver disease 28.8 ADIPOQ INS INSR LEP LEPR RBP4
16 insulin-like growth factor i 28.7 IGF1 IGFBP1 INS INSR IRS1 LEP
17 hypertension, essential 28.7 ADIPOQ ADRB3 INS INSR LEP LPL
18 sleep apnea 28.5 ADIPOQ GHRL IGF1 INS LEP LEPR
19 hyperglycemia 27.9 ADIPOQ DPP4 GCK IGF1 INS INSR
20 hyperinsulinism 27.6 GCK GHRL IGF1 IGFBP1 INS INSR
21 gestational diabetes 27.5 ADIPOQ ADRB3 GCK INS INSR IRS1
22 overnutrition 26.0 ADIPOQ ADRB3 GHRL IGF1 INS IRS1
23 diabetes mellitus 25.3 ADIPOQ ADRB3 DPP4 ENPP1 GCK IGF1
24 diabetes mellitus, noninsulin-dependent 22.9 ADIPOQ ADRB3 DPP4 ENPP1 GCK GHRL
25 body mass index quantitative trait locus 11 21.8 ADIPOQ ADRB3 DPP4 ENPP1 GCK GHRL
26 steatorrhea 11.2
27 mental retardation, skeletal dysplasia, and abducens palsy 11.1
28 growth hormone insensitivity with immunodeficiency 10.9
29 aromatase deficiency 10.9
30 estrogen resistance 10.9
31 pancreatitis, hereditary 10.9
32 insulin autoimmune syndrome 10.9 INS INSR
33 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.8 ADIPOQ INS LMNA
34 acquired generalized lipodystrophy 10.6 ADIPOQ LEP RETN
35 obesity-hypoventilation syndrome 10.6 ADIPOQ LEP RETN
36 nonalcoholic steatohepatitis 10.6 ADIPOQ INS LEP
37 idiopathic recurrent pericarditis 10.6 ADIPOQ LEP RETN
38 mixed cell adenoma 10.6 IGF1 IRS1
39 congenital generalized lipodystrophy 10.5 INS LEP LMNA
40 hutchinson-gilford progeria syndrome 10.5 ADIPOQ ENPP1 LMNA
41 familial partial lipodystrophy 10.5 INS LEP LMNA
42 hyperlipoproteinemia, type v 10.5 INS LPL
43 coronary artery aneurysm 10.5 ADIPOQ LEP RETN
44 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 IGF1 INS INSR
45 hepatitis 10.4
46 inherited metabolic disorder 10.4 ADIPOQ INS LEP
47 secondary adrenal insufficiency 10.4 IGF1 INS
48 donohue syndrome 10.4 IGF1 INS INSR
49 maturity-onset diabetes of the young, type 2 10.4 GCK INS
50 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.4 INS LEP SLC2A4

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance

Symptoms & Phenotypes for Glucose Intolerance

MGI Mouse Phenotypes related to Glucose Intolerance:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.39 IRS1 INS LEP INSR LEPR LPL
2 homeostasis/metabolism MP:0005376 10.39 IRS1 INS LEP INSR LEPR LPL
3 cellular MP:0005384 10.34 IGFBP1 IRS1 INS LEP INSR SLC2A4
4 endocrine/exocrine gland MP:0005379 10.34 IRS1 INS LEP INSR LEPR RBP4
5 growth/size/body region MP:0005378 10.32 IRS1 INS LEP INSR SLC2A4 LEPR
6 cardiovascular system MP:0005385 10.31 IRS1 INS LEP INSR LEPR LPL
7 immune system MP:0005387 10.21 IGFBP1 IRS1 INS LEP INSR SLC2A4
8 liver/biliary system MP:0005370 10.18 IGFBP1 IRS1 INS LEP INSR LEPR
9 mortality/aging MP:0010768 10.1 LEP INSR IRS1 INS SLC2A4 LMNA
10 digestive/alimentary MP:0005381 10.05 INSR INS LEP SLC2A4 LMNA LEPR
11 muscle MP:0005369 10.03 IRS1 INS LEP INSR LEPR LPL
12 integument MP:0010771 10.01 INS LEP LPL LEPR LMNA IGF1
13 renal/urinary system MP:0005367 9.81 INS LEP INSR LEPR LMNA IGF1
14 respiratory system MP:0005388 9.5 INSR LEP LPL LEPR LMNA IGF1
15 skeleton MP:0005390 9.28 IRS1 INS LEP LEPR RBP4 LMNA

Drugs & Therapeutics for Glucose Intolerance

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
2
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
3
Curcumin Approved, Investigational Phase 4 458-37-7 969516
4
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 122320-73-4 77999
5
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
6
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
8
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
9
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
10
Insulin Glargine Approved Phase 4,Phase 3,Phase 1,Not Applicable 160337-95-1
11
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
14
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
15
Voglibose Approved, Investigational Phase 4,Not Applicable 83480-29-9 444020
16
Insulin Aspart Approved Phase 4,Not Applicable 116094-23-6 16132418
17
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Not Applicable 133107-64-9
18
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068 160954
19
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2 44147092
20
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
21
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
22
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
23
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 141758-74-9 15991534
24
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
25
Hydroxychloroquine Approved Phase 4 118-42-3 3652
26
Lisinopril Approved, Investigational Phase 4,Not Applicable 83915-83-7, 76547-98-3 5362119
27
Losartan Approved Phase 4,Phase 2,Not Applicable 114798-26-4 3961
28
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
29
Nateglinide Approved, Investigational Phase 4,Phase 3 105816-04-4 60026
30
Telmisartan Approved, Investigational Phase 4,Phase 2 144701-48-4 65999
31
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
32
Budesonide Approved Phase 4 51333-22-3 63006 5281004
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
35
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
36
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
37
Lopinavir Approved Phase 4 192725-17-0 92727
38
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
39
Zidovudine Approved Phase 4,Phase 3 30516-87-1 35370
40
Trandolapril Approved Phase 4 87679-37-6 5484727
41
Verapamil Approved Phase 4 52-53-9 2520
42
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
43
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
44
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
45
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
46
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
48
Estradiol Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-28-2 5757
49 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Not Applicable 979-32-8
50
Ethinyl Estradiol Approved Phase 4,Not Applicable 57-63-6 5991

Interventional clinical trials:

(show top 50) (show all 1104)
# Name Status NCT ID Phase Drugs
1 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
2 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
3 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
4 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
5 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
6 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
7 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
8 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
9 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
10 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
11 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
12 Sitagliptin and Brown Adipose Tissue Unknown status NCT02294084 Phase 4 Sitagliptin;placebo
13 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
14 Intermittent Hypoxia 2: Cardiovascular and Metabolism Unknown status NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
15 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
16 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
17 Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT) Completed NCT01219231 Phase 4
18 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
19 The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes Completed NCT00546728 Phase 4 Exenatide;Metformin
20 Physical Exercise Versus Rosiglitazone in CAD and Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
21 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes Completed NCT01964703 Phase 4 Rubus occidentalis extract
22 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 Completed NCT01497132 Phase 4 Vitamin D3;Placebo
23 Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study) Completed NCT00928005 Phase 4
24 Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Completed NCT00241072 Phase 4 valsartan
25 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
26 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
27 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
28 Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes Completed NCT02617693 Phase 4
29 Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
30 Sitagliptin in Renal Transplant Recipients Completed NCT00740363 Phase 4 sitagliptin;placebo
31 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
32 The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol;HCTZ;Placebo
33 Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
34 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
35 Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients Completed NCT00319189 Phase 4 Nateglinide
36 Telmisartan and Losartan in Hypertensive IGT Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
37 The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes Completed NCT01181986 Phase 4 Exenatide SC;Exenatide IV;Placebo SC;Exendin-9;Placebo IV
38 Acarbose Cardiovascular Evaluation Trial Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
39 Acute Effect of Exenatide on Brain Glucose Metabolism Completed NCT01588418 Phase 4 Exenatide;Placebo
40 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed NCT00129233 Phase 4 Valsartan;Amlodipine
41 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
42 The Effect of Korean Red Ginseng Supplementation on Glucose Control Completed NCT01911663 Phase 4
43 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
44 Incretins in Impaired Fasting Glucose Completed NCT00364377 Phase 4 Sitagliptin
45 Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction Completed NCT00627744 Phase 4 Sitagliptin
46 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
47 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women Completed NCT00456885 Phase 4 exenatide;Placebo
48 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM Completed NCT01856907 Phase 4 Sitagliptin-Metformin;Metformin;Placebo pill
49 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
50 Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glucose intolerance

Genetic Tests for Glucose Intolerance

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 29

Anatomical Context for Glucose Intolerance

MalaCards organs/tissues related to Glucose Intolerance:

41
Ovary, Heart, Kidney, Endothelial, Testes, Liver, Brain

Publications for Glucose Intolerance

Articles related to Glucose Intolerance:

(show top 50) (show all 791)
# Title Authors Year
1
High-fat diet induces a neurometabolic state characterized by changes in glutamate and N-acetylaspartate pools associated with early glucose intolerance: An in vivo multimodal MRI study. ( 29377412 )
2018
2
Postpartum risk of diabetes and predictive factors for glucose intolerance in East Asian women with gestational diabetes. ( 29596944 )
2018
3
Tau ablation in mice leads to pancreatic I^ cell dysfunction and glucose intolerance. ( 29401605 )
2018
4
Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD. ( 29666152 )
2018
5
Biomarkers of vascular injury and endothelial dysfunction after recent glucose intolerance in pregnancy. ( 29871496 )
2018
6
Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet. ( 29401626 )
2018
7
Obesity: ANGPTL4 - the link binding obesity and glucose intolerance. ( 29611540 )
2018
8
Chaihu-shugan san inhibits inflammatory response to improve insulin signaling in liver and prefrontal cortex of CUMS rats with glucose intolerance. ( 29864926 )
2018
9
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain. ( 29364220 )
2018
10
Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes. ( 29590229 )
2018
11
Arsenic exposure induces glucose intolerance and alters global energy metabolism. ( 29118024 )
2018
12
Circulating B-type natriuretic peptide in women with and without recent gestational diabetes: The impact of current glucose intolerance. ( 29112786 )
2018
13
Ageing potentiates diet-induced glucose intolerance, I^-cell failure and tissue inflammation through TLR4. ( 29426925 )
2018
14
Correction: Intestinal Ralstonia pickettii augments glucose intolerance in obesity. ( 29381738 )
2018
15
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome. ( 29976929 )
2018
16
Wheat bran with enriched gamma-aminobutyric acid attenuates glucose intolerance and hyperinsulinemia induced by a high-fat diet. ( 29693103 )
2018
17
Grifola frondosa (Maitake) extract activates PPARI' and improves glucose intolerance in high-fat diet-induced obese mice. ( 29873587 )
2018
18
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
19
Association of the PCK2 Gene Polymorphism With New-onset Glucose Intolerance in Japanese Kidney Transplant Recipients. ( 29731064 )
2018
20
The Root of Atractylodes macrocephala Koidzumi Prevents Obesity and Glucose Intolerance and Increases Energy Metabolism in Mice. ( 29342124 )
2018
21
Unclassified hepatocellular adenoma in a middle-aged woman with glucose intolerance. ( 29116626 )
2018
22
Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance. ( 29731256 )
2018
23
Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. ( 29842854 )
2018
24
Factors predicting early postpartum glucose intolerance in Japanese women with gestational diabetes mellitus: decision-curve analysis. ( 29706019 )
2018
25
Dietary yeast-derived mannan oligosaccharides have immune-modulatory properties but do not improve high fat diet-induced obesity and glucose intolerance. ( 29723205 )
2018
26
Sarcopoterium spinosum extract improved insulin sensitivity in mice models of glucose intolerance and diabetes. ( 29768504 )
2018
27
Glucose Intolerance ( 29763085 )
2018
28
Dihydrocapsiate supplementation prevented high-fat diet-induced adiposity, hepatic steatosis, glucose intolerance, and gut morphological alterations in mice. ( 29673543 )
2018
29
Chronic sleep disorder induced by psychophysiological stress induces glucose intolerance without adipose inflammation in mice. ( 29288667 )
2018
30
Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome. ( 29707577 )
2018
31
Blockade of Endothelin-1 Receptor Type B Ameliorates Glucose Intolerance and Insulin Resistance in a Mouse Model of Obstructive Sleep Apnea. ( 29896159 )
2018
32
Metformin Mitigates Fibrosis and Glucose Intolerance Induced by Doxorubicin in Subcutaneous Adipose Tissue. ( 29867463 )
2018
33
Clinical implications of combined glucose intolerance in treatment-naA^ve hypertensive patients. ( 29393699 )
2018
34
Glucose effectiveness is a critical pathogenic factor leading to the emergence of glucose intolerance and type 2 diabetes mellitus: an ignored hypothesis. ( 29451713 )
2018
35
Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana. ( 28751150 )
2017
36
Cytosolic Pellino-1-Mediated K63-Linked Ubiquitination of IRF5 in M1 Macrophages Regulates Glucose Intolerance in Obesity. ( 28746869 )
2017
37
Postpartum glucose intolerance: an updated overview. ( 28808874 )
2017
38
Chronic insulin infusion induces reversible glucose intolerance in lean rats yet ameliorates glucose intolerance in obese rats. ( 27871838 )
2017
39
Chow fed UC Davis strain female Lepr fatty Zucker rats exhibit mild glucose intolerance, hypertriglyceridemia, and increased urine volume, all reduced by a Brown Norway strain chromosome 1 congenic donor region. ( 29211750 )
2017
40
Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. ( 28855315 )
2017
41
Royal jelly ameliorates diet-induced obesity and glucose intolerance by promoting brown adipose tissue thermogenesis in mice. ( 28089395 )
2017
42
Alantolactone improves palmitate-induced glucose intolerance and inflammation in both lean and obese states in vitro: Adipocyte and adipocyte-macrophage co-culture system. ( 28599253 )
2017
43
Resolution of glucose intolerance in long-term high-fat, high-sucrose-fed mice. ( 28360081 )
2017
44
Loss of Hepatic Mitochondrial Long-Chain Fatty Acid Oxidation Confers Resistance to Diet-Induced Obesity and Glucose Intolerance. ( 28723568 )
2017
45
Banxia-houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain. ( 28782622 )
2017
46
<i>Flos Lonicera</i> Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. ( 29204141 )
2017
47
Implementing a Reminder System in the Northern Part of Belgium to Stimulate Postpartum Screening for Glucose Intolerance in Women with Gestational Diabetes: The &amp;quot;Sweet Pregnancy&amp;quot; Project. ( 28775742 )
2017
48
Host-microbiota interaction induces bi-phasic inflammation and glucose intolerance in mice. ( 29107285 )
2017
49
Hyperhomocysteinemia as a Metabolic Risk Factor for Glucose Intolerance Among High-Risk Groups of Chinese Adults. ( 28591087 )
2017
50
Targeting viperin improves diet-induced glucose intolerance but not adipose tissue inflammation. ( 29254175 )
2017

Variations for Glucose Intolerance

ClinVar genetic disease variations for Glucose Intolerance:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh37 Chromosome MT, 3243: 3243
2 MT-TL1 m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh38 Chromosome MT, 3243: 3243

Expression for Glucose Intolerance

Search GEO for disease gene expression data for Glucose Intolerance.

Pathways for Glucose Intolerance

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 ADIPOQ ADRB3 INS INSR IRS1 LEP
2
Show member pathways
12.85 GCK IGF1 INS INSR IRS1 SLC2A4
3
Show member pathways
12.81 ADIPOQ INS INSR IRS1 LEP RBP4
4
Show member pathways
12.48 ENPP1 INS INSR IRS1 LPL SLC2A4
5
Show member pathways
12.44 GCK INS IRS1 LEP LEPR
6 12.44 ADIPOQ ENPP1 IGFBP1 INS INSR IRS1
7
Show member pathways
12.41 IGF1 INS INSR IRS1
8
Show member pathways
12.26 ADRB3 IGF1 INSR IRS1
9
Show member pathways
12.22 DPP4 GHRL IGF1 INS LEP
10
Show member pathways
12.18 INS INSR IRS1 LEP SLC2A4
11
Show member pathways
12.17 ADIPOQ IGF1 INS INSR IRS1 LEP
12
Show member pathways
12.11 ADIPOQ IGF1 INS INSR IRS1
13
Show member pathways
12.01 IGF1 INS INSR IRS1 SLC2A4
14
Show member pathways
11.91 INS INSR IRS1 SLC2A4
15 11.82 IGF1 INS INSR
16
Show member pathways
11.72 ADIPOQ GCK INS INSR IRS1 SLC2A4
17 11.68 INS LPL RBP4
18 11.62 INS INSR IRS1
19 11.61 GCK IGFBP1 LEP
20 11.6 ADIPOQ IRS1 LEP LEPR SLC2A4
21 11.54 ADRB3 INS INSR IRS1
22 11.51 IRS1 LEP LEPR SLC2A4
23 11.48 IGF1 INS INSR
24 11.43 GCK IGFBP1 INS
25 11.42 INS INSR IRS1 LEP LEPR
26 11.41 INS INSR IRS1
27 11.4 ADIPOQ IGF1 INS IRS1 LEP LMNA
28 11.33 IGF1 INS INSR IRS1
29 11.22 INS INSR SLC2A4
30
Show member pathways
10.95 INSR IRS1 SLC2A4
31 10.86 INS SLC2A4
32 10.7 ADIPOQ INSR IRS1 LEP SLC2A4

GO Terms for Glucose Intolerance

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.65 ADIPOQ DPP4 ENPP1 LPL SLC2A4
2 extracellular space GO:0005615 9.65 ADIPOQ ENPP1 GHRL IGF1 IGFBP1 INS
3 extracellular region GO:0005576 9.44 ADIPOQ DPP4 ENPP1 GHRL IGF1 IGFBP1
4 insulin receptor complex GO:0005899 9.16 INSR IRS1

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.95 ADRB3 GCK INS INSR SLC2A4
2 positive regulation of protein kinase B signaling GO:0051897 9.93 INS INSR IRS1 LEP
3 activation of MAPK activity GO:0000187 9.9 GHRL IGF1 INS INSR
4 response to ethanol GO:0045471 9.89 ADIPOQ LEP RBP4 SLC2A4
5 positive regulation of MAPK cascade GO:0043410 9.88 ADRB3 IGF1 INS INSR LEP
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 ADIPOQ IGF1 INS
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 IGF1 INS LEP
8 response to insulin GO:0032868 9.85 IGF1 INS IRS1 LEP RETN
9 regulation of insulin secretion GO:0050796 9.84 DPP4 GCK LEP
10 insulin receptor signaling pathway GO:0008286 9.84 IGFBP1 INS INSR IRS1
11 glucose metabolic process GO:0006006 9.83 ADIPOQ GCK GHRL INS LEP
12 generation of precursor metabolites and energy GO:0006091 9.82 ADIPOQ ADRB3 ENPP1
13 response to glucose GO:0009749 9.81 ADIPOQ IGF1 INS LPL
14 positive regulation of insulin secretion GO:0032024 9.8 GCK GHRL RBP4
15 response to nutrient levels GO:0031667 9.8 ADIPOQ GHRL IGF1 INS LEP
16 positive regulation of DNA replication GO:0045740 9.79 IGF1 INS INSR
17 activation of protein kinase B activity GO:0032148 9.78 IGF1 INS INSR
18 brown fat cell differentiation GO:0050873 9.76 ADIPOQ ADRB3 SLC2A4
19 positive regulation of mitotic nuclear division GO:0045840 9.75 IGF1 INS INSR
20 cellular response to insulin stimulus GO:0032869 9.73 ADIPOQ ENPP1 GCK INSR IRS1 SLC2A4
21 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.7 IGF1 LMNA
22 positive regulation of cellular protein metabolic process GO:0032270 9.7 ADIPOQ INS
23 positive regulation of glycolytic process GO:0045821 9.7 IGF1 INS INSR
24 insulin-like growth factor receptor signaling pathway GO:0048009 9.69 IGF1 IRS1
25 negative regulation of glucose import GO:0046325 9.69 ENPP1 LEP
26 sexual reproduction GO:0019953 9.68 LEP LEPR
27 negative regulation of protein autophosphorylation GO:0031953 9.68 ADIPOQ ENPP1
28 adult feeding behavior GO:0008343 9.68 GHRL LEP
29 cellular response to leptin stimulus GO:0044320 9.68 GCK LEP
30 leptin-mediated signaling pathway GO:0033210 9.67 LEP LEPR
31 energy reserve metabolic process GO:0006112 9.67 ADRB3 LEP LEPR
32 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 IGF1 INS IRS1 LEP
33 regulation of bone remodeling GO:0046850 9.66 LEP LEPR
34 negative regulation of feeding behavior GO:2000252 9.66 INS RETN
35 positive regulation of respiratory burst GO:0060267 9.65 INS INSR
36 neuron projection maintenance GO:1990535 9.65 INS INSR
37 regulation of protein localization to nucleus GO:1900180 9.65 LEP LMNA
38 bone mineralization involved in bone maturation GO:0035630 9.64 IGF1 LEP
39 positive regulation of developmental growth GO:0048639 9.63 INSR LEP
40 negative regulation of gluconeogenesis GO:0045721 9.62 ADIPOQ GCK INS LEPR
41 bone growth GO:0098868 9.57 LEP LEPR
42 positive regulation of glucose import GO:0046326 9.55 ADIPOQ IGF1 INS INSR IRS1
43 positive regulation of glycogen biosynthetic process GO:0045725 9.35 GCK IGF1 INS INSR IRS1
44 glucose homeostasis GO:0042593 9.32 ADIPOQ GCK IGF1 INS INSR IRS1
45 negative regulation of apoptotic process GO:0043066 10.09 GHRL IGF1 INS INSR LEP
46 positive regulation of cell proliferation GO:0008284 10.09 DPP4 IGF1 INS INSR IRS1 LEP
47 regulation of signaling receptor activity GO:0010469 10.03 ADIPOQ GHRL IGF1 INS LEP RETN

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.77 ADIPOQ DPP4 IGFBP1 LEP LPL
2 insulin receptor binding GO:0005158 9.46 ENPP1 IGF1 INS IRS1
3 insulin-like growth factor I binding GO:0031994 9.4 IGFBP1 INSR
4 insulin-like growth factor II binding GO:0031995 9.32 IGFBP1 INSR
5 receptor activator activity GO:0030546 9.26 IGF1 INS
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS INSR IRS1
7 hormone activity GO:0005179 9.1 ADIPOQ GHRL IGF1 INS LEP RETN
8 protein binding GO:0005515 10.36 ADIPOQ ADRB3 DPP4 ENPP1 GCK GHRL

Sources for Glucose Intolerance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....